Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,424.00
Ask: 12,426.00
Change: 58.00 (0.47%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,470.00
Low: 12,322.00
Prev. Close: 12,346.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Stabilisation Notice

19 Nov 2014 09:41

RNS Number : 4348X
Citigroup Global Markets Limited
19 November 2014
 



19th November 2014

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

AstraZeneca PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

Issuer:

AstraZeneca PLC

Guarantor (if any):

Aggregate nominal amount:

€ TBC

Description:

Senior Unsecured REGS Only

Offer price:

TBC

Other offer terms

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

19th November 2014

Stabilisation period expected to end no later than:

20th December 2014 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STABLBLTMBIBMMI
Date   Source Headline
7th Sep 201712:39 pmRNSCelgene and AZ update on Fusion trial programme
7th Sep 20177:00 amRNSAZ Duaklir improves lung function in COPD patients
7th Sep 20177:00 amRNSAZ tezepelumab cuts exacerbations in severe asthma
5th Sep 20177:00 amRNSDirectorate Change
1st Sep 20173:00 pmRNSTotal Voting Rights
29th Aug 20177:00 amRNSFaslodex gets US FDA OK for expanded use in breast
18th Aug 20177:00 amRNSLynparza gets broad FDA approval in ovarian cancer
16th Aug 20177:00 amRNSDirectorate Change
14th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20171:30 pmRNSPublication of a Prospectus
2nd Aug 20177:00 amRNSAZ acalabrutinib submission accepted by US FDA
1st Aug 20173:00 pmRNSTotal Voting Rights
1st Aug 20177:00 amRNSBTD for AZ's acalabrutinib in mantle cell lymphoma
31st Jul 20177:00 amRNSImfinzi granted BTD by US FDA for Stage III nsclc
28th Jul 201711:00 amRNSDirector/PDMR Shareholding
27th Jul 20177:15 amRNSTagrisso significantly improves FLAURA
27th Jul 20177:11 amRNSAZ reports initial results from MYSTIC lung trial
27th Jul 20177:06 amRNSAZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27th Jul 20177:00 amRNSAstraZeneca PLC - H1 2017 Results
26th Jul 20174:46 pmRNSFaslodex receives EU approval for 1L breast cancer
21st Jul 20173:45 pmRNSHolding(s) in Company
3rd Jul 20172:59 pmRNSTotal Voting Rights
3rd Jul 20177:00 amRNSAZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
3rd Jul 20177:00 amRNSAZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23rd Jun 201712:46 pmRNSFaslodex CHMP positive opinion in 1L breast cancer
7th Jun 20177:13 amRNSAZ agreement with Grünenthal for rights to Zomig
6th Jun 20177:00 amRNSASTRAZENECA PRICES A $2BN BOND ISSUE
5th Jun 20177:00 amRNSLYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
1st Jun 20173:00 pmRNSBlock listing Interim Review
1st Jun 20173:00 pmRNSTotal Voting Rights
31st May 20177:00 amRNSDirectorate Change
24th May 20173:00 pmRNSDirector/PDMR Shareholding
23rd May 20177:00 amRNSBydureon EXSCEL trial meets T2D safety objective
22nd May 20177:00 amRNSAZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16th May 20173:00 pmRNSDirector/PDMR Shareholding
12th May 20177:00 amRNSIMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10th May 20177:00 amRNSAZ updates on tralokinumab trial in severe asthma
2nd May 20172:00 pmRNSTotal Voting Rights
2nd May 20177:00 amRNSDURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27th Apr 20175:30 pmRNSResult of AGM
27th Apr 20177:00 amRNSAstraZeneca: Q1 2017 Results
25th Apr 20171:30 pmRNSTAGRISSO RECEIVES FULL APPROVAL IN THE EU
12th Apr 20175:34 pmRNSNotification of Major Interest in Shares
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20177:01 amRNSTagrisso (osimertinib) receives FDA full approval
31st Mar 20177:00 amRNSAZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28th Mar 20174:00 pmRNSDirector/PDMR Shareholding
27th Mar 20173:00 pmRNSDirector/PDMR Shareholding
17th Mar 20177:00 amRNSUS FDA issues CRL for ZS-9 in hyperkalaemia
16th Mar 201711:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.